Marine Compound Enterocin Lowers Cholesterol by Targeting Liver Protein ASGR1
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
Summary
Scientists discovered enterocin, a natural compound from marine bacteria, that significantly lowers cholesterol by targeting a specific liver protein called ASGR1. In laboratory studies, enterocin enhanced the liver's ability to remove cholesterol from cells and improved fat metabolism. When tested in mice fed high-fat diets, the compound reduced body fat, improved cholesterol profiles, and enhanced cholesterol elimination through feces. The compound worked as effectively as established cholesterol medications like atorvastatin, but through a completely different mechanism that specifically targets liver metabolism without affecting intestinal fat absorption.
Detailed Summary
Cardiovascular disease remains a leading cause of death, making the discovery of new cholesterol-lowering treatments crucial for longevity and health optimization. This research represents a significant breakthrough in understanding how natural compounds can target specific pathways involved in cholesterol metabolism.
Researchers isolated enterocin, a unique polyketide compound, from marine-derived Streptomyces bacteria using activity-guided screening for cholesterol-modulating effects. They tested the compound in human liver cell lines and two different mouse models fed high-fat diets, comparing results to established medications.
Enterocin works by directly binding to and degrading ASGR1, a liver protein that normally inhibits cholesterol removal. This triggers a cascade of beneficial effects: activation of AMPK (a key metabolic regulator), upregulation of cholesterol transport proteins, and enhanced cholesterol elimination. In mice, enterocin reduced visceral and subcutaneous fat, decreased harmful cholesterol levels, increased beneficial HDL cholesterol, and improved liver fat accumulation.
For longevity and metabolic health, this discovery offers potential advantages over current treatments. Unlike statins that block cholesterol production, enterocin enhances the body's natural cholesterol removal mechanisms. The compound showed effectiveness comparable to atorvastatin but with a novel mechanism that could complement existing therapies.
However, this remains early-stage research conducted only in laboratory settings and animal models. Human clinical trials are needed to establish safety, optimal dosing, and long-term effects before any therapeutic applications can be considered.
Key Findings
- Enterocin reduced total cholesterol, triglycerides, and LDL while increasing HDL in high-fat diet mice
- The compound enhanced cholesterol removal by targeting liver protein ASGR1 for degradation
- Enterocin showed effectiveness equal to or better than atorvastatin in cholesterol-lowering
- Treatment reduced both visceral and subcutaneous fat accumulation in mice
- The compound specifically targets liver metabolism without affecting intestinal fat absorption
Methodology
Researchers used human liver cell lines (Huh-7 and HepG2) and two mouse models: wild-type and LDLR-knockout mice fed high-fat diets. The study included comparisons with established treatments atorvastatin and GW3965, with comprehensive analysis of lipid profiles, protein expression, and metabolic pathways.
Study Limitations
This study was conducted only in laboratory cell cultures and mouse models, requiring human clinical trials to establish safety and efficacy. The long-term effects, optimal dosing, and potential interactions with other medications remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.